Meeting
2021 ASCO Annual Meeting
IL-1 receptor antagonist for prevention of severe immune effector cell-associated neurotoxicity syndrome.
Authors
Caspian Oliai
UCLA Medical Center, Los Angeles, CA
Caspian Oliai , Anna Crosetti , Sven De Vos , Herbert Eradat , Monica Diane Mead , Sarah Marie Larson , Steven Tsai , Annabel Liu , Gina Khachatrian , Christopher Hannigan , Reiko E. Yamada , Neiki Rokni , John Timmerman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT4205838
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 7566)
DOI
10.1200/JCO.2021.39.15_suppl.7566
Abstract #
7566
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Rates of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) from Center for International Blood and Marrow Transplant Research (CIBMTR) data on US subjects (SUBJ) with lymphoma following chimeric antigen receptor T cell therapy (CAR-T).
First Author: Matthew J. Frigault
Poster
2020 ASCO Virtual Scientific Program
Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel).
First Author: Paolo Strati
Poster
2020 ASCO Virtual Scientific Program
Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel).
First Author: Sairah Ahmed
Poster
2018 ASCO Annual Meeting
Which is better in CD19 CAR-T treatment of r/r B-ALL, CD28 or 4-1BB? A parallel trial under the same manufacturing process.
First Author: Peihua Lu